Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial - Quiz - MDSpire

Efficacy and Safety of Deucravacitinib in Patients with Active Psoriatic Arthritis: Results from the Phase 3 POETYK PsA-2 Trial Over 52 Weeks

  • By

  • Philip J. Mease

  • Vinod Chandran

  • April W. Armstrong

  • Ricardo Blanco

  • Alexis Ogdie

  • Evan L. Siegel

  • Alice B. Gottlieb

  • Xiaofeng Zeng

  • Diamant Thaçi

  • Mitsumasa Kishimoto

  • Hendrik Schulze-Koops

  • Alan Kivitz

  • Eva Dokoupilová

  • Akimichi Morita

  • Eric M. Ruderman

  • Michael Plewinski

  • Kejia Wang

  • Caroline Sardinas

  • Eleni Vritzali

  • John Vaile

  • Atul Deodhar

  • July 20, 2026

Share

Original Source(s)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

  • by Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

  • July 20, 2026

Related Content

Maresin-1 and maresin-2 as synovial fluid biomarkers in psoriatic, rheumatoid, and osteoarthritis

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Case report : Early-Onset Juvenile Psoriatic Arthritis Presenting at 15 Months: A Diagnostic Challenge in Infancy